

Dean A Follmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9131276/publications.pdf>

Version: 2024-02-01

156
papers

21,603
citations

46918

47
h-index

10708

138
g-index

164
all docs

164
docs citations

164
times ranked

32463
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
2	Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2402-2410.	1.8	3,201
3	Variance imputation for overviews of clinical trials with continuous response. <i>Journal of Clinical Epidemiology</i> , 1992, 45, 769-773.	2.4	1,137
4	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	6.0	788
5	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 619-629.	13.9	741
6	Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2012, 367, 1508-1518.	13.9	496
7	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
8	Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 1130.	3.8	353
9	Electrical Storm Presages Nonsudden Death. <i>Circulation</i> , 2001, 103, 2066-2071.	1.6	346
10	Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2005, 191, 666-677.	1.9	333
11	An Approximate Generalized Linear Model with Random Effects for Informative Missing Data. <i>Biometrics</i> , 1995, 51, 151.	0.8	231
12	Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man. <i>PLoS Pathogens</i> , 2009, 5, e1000321.	2.1	213
13	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). <i>Clinical Infectious Diseases</i> , 2015, 61, 800-806.	2.9	206
14	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	13.9	199
15	The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. <i>Journal of the American College of Cardiology</i> , 2003, 42, 914-922.	1.2	198
16	Intracellular interferon- γ in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. <i>Blood</i> , 2002, 100, 1185-1191.	0.6	187
17	A comparative analysis of the results from 4 trials of β -blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. <i>Journal of Cardiac Failure</i> , 2003, 9, 354-363.	0.7	164
18	Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2006, 203, 2339-2350.	4.2	162

#	ARTICLE	IF	CITATIONS
19	CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral Transmission. <i>Journal of Infectious Diseases</i> , 2010, 201, 178-185.	1.9	145
20	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
21	Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. <i>Blood</i> , 2001, 98, 3513-3519.	0.6	135
22	High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial. <i>Journal of Infectious Diseases</i> , 2011, 203, 756-764.	1.9	132
23	Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. <i>Journal of Pediatrics</i> , 1995, 127, 137-146.	0.9	126
24	Predictors of Mortality and Mortality From Cardiac Causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry. <i>Circulation</i> , 2000, 101, 2682-2689.	1.6	119
25	Valid Inference in Random Effects Meta-Analysis. <i>Biometrics</i> , 1999, 55, 732-737.	0.8	112
26	HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19851-19856.	3.3	111
27	Mycobacterial Antigen Driven Activation of CD14+CD16 ⁺ Monocytes Is a Predictor of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. <i>PLoS Pathogens</i> , 2014, 10, e1004433.	2.1	111
28	Generalizing Logistic Regression by Nonparametric Mixing. <i>Journal of the American Statistical Association</i> , 1989, 84, 295-300.	1.8	106
29	Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial. <i>Journal of the American College of Cardiology</i> , 1999, 34, 325-333.	1.2	103
30	Multiple Outputation: Inference for Complex Clustered Data by Averaging Analyses from Independent Data. <i>Biometrics</i> , 2003, 59, 420-429.	0.8	96
31	Augmented Designs to Assess Immune Response in Vaccine Trials. <i>Biometrics</i> , 2006, 62, 1161-1169.	0.8	96
32	A single injection of crystallizable fragment domain ⁶⁶ -modified antibodies elicits durable protection from SHIV infection. <i>Nature Medicine</i> , 2018, 24, 610-616.	15.2	94
33	Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk Evaluation. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 386-393.	0.6	93
34	Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. <i>PLoS ONE</i> , 2012, 7, e24243.	1.1	89
35	Lysis of Endogenously Infected CD4+ T Cell Blasts by rIL-2 Activated Autologous Natural Killer Cells from HIV-Infected Viremic Individuals. <i>PLoS Pathogens</i> , 2008, 4, e1000101.	2.1	88
36	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	2.0	86

#	ARTICLE	IF	CITATIONS
37	A Simple Multivariate Test for One-Sided Alternatives. <i>Journal of the American Statistical Association</i> , 1996, 91, 854-861.	1.8	80
38	Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2004, 78, 10566-10573.	1.5	68
39	Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis with Vasopressor-dependent Shock: A Propensity-Score Matched Analysis from 130 US Hospitals. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw871.	2.9	65
40	Multivariate tests for multiple endpoints in clinical trials. <i>Statistics in Medicine</i> , 1995, 14, 1163-1175.	0.8	63
41	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. <i>Clinical Trials</i> , 2016, 13, 49-56.	0.7	63
42	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	2.0	63
43	Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers. <i>Journal of Virology</i> , 2009, 83, 11857-11861.	1.5	62
44	Modeling Repeated Count Data Subject to Informative Dropout. <i>Biometrics</i> , 2000, 56, 667-677.	0.8	59
45	Endpoints for randomized controlled clinical trials for COVID-19 treatments. <i>Clinical Trials</i> , 2020, 17, 472-482.	0.7	55
46	Anthrax Vaccine-Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol Challenge. <i>Science Translational Medicine</i> , 2012, 4, 151ra126.	5.8	52
47	Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5056-5061.	3.3	50
48	Development of Functional and Molecular Correlates of Vaccine-Induced Protection for a Model Intracellular Pathogen, <i>F. tularensis</i> LVS. <i>PLoS Pathogens</i> , 2012, 8, e1002494.	2.1	50
49	Consistent estimation in the rasch model based on nonparametric margins. <i>Psychometrika</i> , 1988, 53, 553-562.	1.2	49
50	Identifiability of finite mixtures of logistic regression models. <i>Journal of Statistical Planning and Inference</i> , 1991, 27, 375-381.	0.4	49
51	Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1093-1099.	1.2	49
52	Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. <i>Blood</i> , 2004, 103, 3282-3286.	0.6	47
53	On the Effect of Treatment among Would-Be Treatment Compliers: An Analysis of the Multiple Risk Factor Intervention Trial. <i>Journal of the American Statistical Association</i> , 2000, 95, 1101-1109.	1.8	44
54	Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2002, 119, 97-105.	1.2	42

#	ARTICLE	IF	CITATIONS
55	The use of subjective rankings in clinical trials with an application to cardiovascular disease. <i>Statistics in Medicine</i> , 1992, 11, 427-437.	0.8	41
56	Neutralizing Antibody Titers Conferring Protection to Macaques from a Simian/Human Immunodeficiency Virus Challenge Using the TZM-bl Assay. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 89-98.	0.5	40
57	Interferon- β Produces Significant Decreases in HIV Load. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 461-464.	0.5	37
58	Distinguishing Heterogeneity From Decreasing Hazard Rates. <i>Technometrics</i> , 1988, 30, 389-396.	1.3	35
59	Parametric and semiparametric approaches to testing for seasonal trend in serial count data. <i>Biostatistics</i> , 2002, 3, 289-298.	0.9	35
60	A Latent Autoregressive Model for Longitudinal Binary Data Subject to Informative Missingness. <i>Biometrics</i> , 2002, 58, 631-642.	0.8	35
61	Use of Summary Measures to Adjust for Informative Missingness in Repeated Measures Data with Random Effects. <i>Biometrics</i> , 1999, 55, 75-84.	0.8	33
62	Design and Analysis of Crossover Trials for Absorbing Binary Endpoints. <i>Biometrics</i> , 2010, 66, 958-965.	0.8	33
63	A Random Effects Transition Model For Longitudinal Binary Data With Informative Missingness. <i>Statistica Neerlandica</i> , 2003, 57, 100-111.	0.9	32
64	Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model. <i>Annals of Applied Statistics</i> , 2008, 2, 386-407.	0.5	32
65	Semiparametric dimension reduction estimation for mean response with missing data. <i>Biometrika</i> , 2010, 97, 305-319.	1.3	32
66	T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. <i>The Hematology Journal</i> , 2003, 4, 18-25.	2.0	31
67	Designing Monte Carlo Implementations of Permutation or Bootstrap Hypothesis Tests. <i>American Statistician</i> , 2002, 56, 63-70.	0.9	28
68	Multiple Comparisons with Control in a Single Experiment versus Separate Experiments: Why Do We Feel Differently?. <i>American Statistician</i> , 1995, 49, 144-149.	0.9	26
69	Accounting for Variability in Sample Size Estimation with Applications to Nonadherence and Estimation of Variance and Effect Size. <i>Biometrics</i> , 2007, 63, 465-474.	0.8	26
70	Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. <i>Journal of Virological Methods</i> , 2018, 255, 84-90.	1.0	26
71	Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses. <i>Journal of Infectious Diseases</i> , 2021, 224, 49-59.	1.9	26
72	Chopâ€Lump Tests for Vaccine Trials. <i>Biometrics</i> , 2009, 65, 885-893.	0.8	25

#	ARTICLE	IF	CITATIONS
73	A maximum pseudo-profile likelihood estimator for the Cox model under length-biased sampling. <i>Biometrika</i> , 2012, 99, 199-210.	1.3	25
74	Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	25
75	Learning Curves, Personal Characteristics, and Job Performance. <i>Journal of Labor Economics</i> , 1989, 7, 129-146.	1.5	24
76	A Multivariate Test of Interaction for Use in Clinical Trials. <i>Biometrics</i> , 1999, 55, 1151-1155.	0.8	23
77	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	1.1	23
78	Causal estimands and confidence intervals associated with Wilcoxonâ€Mannâ€Whitney tests in randomized experiments. <i>Statistics in Medicine</i> , 2018, 37, 2923-2937.	0.8	21
79	A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	21
80	A valid formulation of the analysis of noninferiority trials under random effects meta-analysis. <i>Biostatistics</i> , 2012, 13, 637-649.	0.9	20
81	Regression analysis based on pairwise ordering of patients' clinical histories. <i>Statistics in Medicine</i> , 2002, 21, 3353-3367.	0.8	19
82	Random effects and latent processes approaches for analyzing binary longitudinal data with missingness: a comparison of approaches using opiate clinical trial data. <i>Statistical Methods in Medical Research</i> , 2007, 16, 417-439.	0.7	19
83	Estimation of mean response via the effective balancing score. <i>Biometrika</i> , 2014, 101, 613-624.	1.3	19
84	The Accelerated Biased Coin Up-and-Down Design in Phase I Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2004, 14, 249-260.	0.4	18
85	Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence. <i>PLoS ONE</i> , 2016, 11, e0159727.	1.1	17
86	Comment: Fundamentals and Innovation in Antibiotic Trials. <i>Statistics in Biopharmaceutical Research</i> , 2015, 7, 331-336.	0.6	15
87	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	2.0	15
88	Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. <i>Blood</i> , 2004, 103, 4070-4077.	0.6	14
89	Contribution of TCR- $\hat{\nu}^2$ Locus and HLA to the Shape of the Mature Human $\hat{\nu}^2$ Repertoire. <i>Journal of Immunology</i> , 2008, 180, 6484-6489.	0.4	14
90	The effect of estimation and biasing strategies on selection bias in clinical trials with permuted blocks. <i>Journal of Statistical Planning and Inference</i> , 1994, 39, 1-17.	0.4	13

#	ARTICLE	IF	CITATIONS
91	Bayesian Monitoring of Event Rates with Censored Data. <i>Biometrics</i> , 1999, 55, 603-607.	0.8	13
92	Cluster without fluster: The effect of correlated outcomes on inference in randomized clinical trials. <i>Statistics in Medicine</i> , 2008, 27, 795-809.	0.8	13
93	Analysis of ordered composite endpoints. <i>Statistics in Medicine</i> , 2020, 39, 602-616.	0.8	13
94	Empirical Likelihood-Based Estimation of the Treatment Effect in a Pretestâ€œPosttest Study. <i>Journal of the American Statistical Association</i> , 2008, 103, 1270-1280.	1.8	12
95	Assessing vaccine durability in randomized trials following placebo crossover. <i>Statistics in Medicine</i> , 2021, 40, 5983-6007.	0.8	12
96	Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). <i>Clinical Infectious Diseases</i> , 2019, 68, 1961-1967.	2.9	11
97	Personal characteristics, unemployment insurance, and the duration of unemployment. <i>Journal of Econometrics</i> , 1990, 45, 351-366.	3.5	10
98	Semiparametric Double Balancing Score Estimation for Incomplete Data With Ignorable Missingness. <i>Journal of the American Statistical Association</i> , 2012, 107, 247-257.	1.8	10
99	Post-treatment Lyme disease symptoms score: Developing a new tool for research. <i>PLoS ONE</i> , 2019, 14, e0225012.	1.1	10
100	A model checking method for the proportional hazards model with recurrent gap time data. <i>Biostatistics</i> , 2011, 12, 535-547.	0.9	9
101	Discordant minimum inhibitory concentration analysis: A new path to licensure for anti-infective drugs. <i>Clinical Trials</i> , 2013, 10, 876-885.	0.7	9
102	Exact Inference for Complex Clustered Data Using Within-Cluster Resampling. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 850-869.	0.4	8
103	Dimension reduced kernel estimation for distribution function with incomplete data. <i>Journal of Statistical Planning and Inference</i> , 2011, 141, 3084-3093.	0.4	8
104	Incorporating Founder Virus Information in Vaccine Field Trials. <i>Biometrics</i> , 2015, 71, 386-396.	0.8	8
105	Recurrent event data analysis with intermittently observed timeâ€œvarying covariates. <i>Statistics in Medicine</i> , 2016, 35, 3049-3065.	0.8	8
106	Streptococcal group A, C and G pharyngitis in school children: a prospective cohort study in Southern India. <i>Epidemiology and Infection</i> , 2018, 146, 848-853.	1.0	8
107	Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms. <i>American Journal of Infection Control</i> , 2019, 47, 1040-1047.	1.1	8
108	Gender differences in the psychosocial variance of Framingham and Bortner type a measures. <i>Journal of Psychosomatic Research</i> , 1993, 37, 709-716.	1.2	7

#	ARTICLE	IF	CITATIONS
109	A Simple Permutation-Type Method for Testing Circular Uniformity with Correlated Angular Measurements. <i>Biometrics</i> , 1999, 55, 782-791.	0.8	7
110	Augmented trial designs for evaluation of principal surrogates. <i>Biostatistics</i> , 2016, 17, 453-467.	0.9	7
111	Repeated Probit Regression When Covariates Are Measured With Error. <i>Biometrics</i> , 1999, 55, 403-409.	0.8	6
112	Vaccine design via nonnegative lasso-based variable selection. <i>Statistics in Medicine</i> , 2015, 34, 1791-1798.	0.8	6
113	Reply to Phillips, Morris, and Walker. <i>Clinical Infectious Diseases</i> , 2016, 62, 815-816.	2.9	5
114	A boundary-optimized rejection region test for the two-sample binomial problem. <i>Statistics in Medicine</i> , 2018, 37, 1047-1058.	0.8	5
115	Joint testing of overall and simple effects for the two-by-two factorial trial design. <i>Clinical Trials</i> , 2021, 18, 521-528.	0.7	5
116	Vaccine efficacy at a point in time. <i>Biostatistics</i> , 2023, 24, 603-617.	0.9	5
117	Sieve Analysis Using the Number of Infecting Pathogens. <i>Biometrics</i> , 2018, 74, 1023-1033.	0.8	4
118	Conditional independence test by generalized Kendall's tau with generalized odds ratio. <i>Statistical Methods in Medical Research</i> , 2018, 27, 3224-3235.	0.7	4
119	Reliably picking the best endpoint. <i>Statistics in Medicine</i> , 2018, 37, 4374-4385.	0.8	4
120	Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 125-30.	0.6	4
121	Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy. <i>Annals of Internal Medicine</i> , 2022, 175, 444-445.	2.0	4
122	A New Approach to Assessing Regional and Global Myocardial Contractility. <i>Echocardiography</i> , 1997, 14, 1-7.	0.3	3
123	Testing for treatment and interaction effects in semi-parametric analysis of covariance. <i>Statistics in Medicine</i> , 2001, 20, 1-19.	0.8	3
124	A nonparametric likelihood test for detecting discordance between two measurements with application to censored viral load determinations. <i>Statistics in Medicine</i> , 2008, 27, 4489-4501.	0.8	3
125	On Causal Inferences for Personalized Medicine: How Hidden Causal Assumptions Led to Erroneous Causal Claims About the D-Value. <i>American Statistician</i> , 2020, 74, 243-248.	0.9	3
126	Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated. <i>Statistics in Medicine</i> , 2022, 41, 3076-3089.	0.8	3

#	ARTICLE	IF	CITATIONS
127	A Restricted Test of Circadian Rhythm. <i>Journal of the American Statistical Association</i> , 1997, 92, 717-724.	1.8	2
128	Comparing HLA antigen frequencies between two groups of patients. <i>Statistics in Medicine</i> , 2003, 22, 1999-2013.	0.8	2
129	A hierarchical rank test for crossover trials with censored data. <i>Statistics in Medicine</i> , 2011, 30, 3507-3519.	0.8	2
130	Non-inferiority tests for anti-infective drugs using control group quantiles. <i>Clinical Trials</i> , 2016, 13, 632-640.	0.7	2
131	Novel Superiority Tests for Anti-Infective Drug Trials: Three Examples. <i>Statistics in Biopharmaceutical Research</i> , 2018, 10, 9-17.	0.6	2
132	Tomorrow's HIV Prevention Trials of Vaccines and Antibodies. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
133	Comment. <i>Statistics in Medicine</i> , 2021, 40, 2526-2527.	0.8	2
134	The mechanistic analysis of founder virus data in challenge models. <i>Statistics in Medicine</i> , 2021, 40, 4492-4504.	0.8	2
135	Dynamic Comparison of Kaplan-Meier Proportions: Monitoring a Randomized Clinical Trial with a Long-Term Binary Endpoint. <i>Biometrics</i> , 2008, 64, 189-197.	0.8	1
136	An Augmented Probit Model for Missing Predictable Covariates in Quantal Bioassay with Small Sample Size. <i>Biometrics</i> , 2011, 67, 1127-1134.	0.8	1
137	Matched Longitudinal Analysis of Biomarkers Associated with Survival. <i>Vaccine Journal</i> , 2014, 21, 1145-1152.	3.2	1
138	Estimating the burden of pertussis in Mexican adolescents from paired serological data by using a bivariate mixture model. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2014, 63, 621-637.	0.5	1
139	Who really gets strep sore throat? Confounding and effect modification of a time-varying exposure on recurrent events. <i>Statistics in Medicine</i> , 2016, 35, 4398-4412.	0.8	1
140	Half blind superiority tests for clinical trials of anti-infective drugs. <i>Statistics in Medicine</i> , 2019, 38, 31-43.	0.8	1
141	Predictive cluster level surrogacy in the presence of interference. <i>Biostatistics</i> , 2020, 21, e33-e46.	0.9	1
142	A unified evaluation of differential vaccine efficacy. <i>Biometrics</i> , 2020, 76, 1053-1063.	0.8	1
143	Discussion on "estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian. <i>Biometrics</i> , 2022, 78, 844-847.	0.8	1
144	Semiparametric mixture survival model with application to MRFIT study. <i>Statistics and Its Interface</i> , 2014, 7, 19-26.	0.2	1

#	ARTICLE	IF	CITATIONS
145	Branching process models to identify risk factors for infectious disease transmission. Journal of Computational and Graphical Statistics, 0, , 1-29.	0.9	1
146	Essentials of Randomized Clinical Trials. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 254-259.	0.5	0
147	Statistical methods for active extension trials. Statistics in Medicine, 2007, 26, 2433-2448.	0.8	0
148	A test of location for exchangeable multivariate normal data with unknown correlation. Journal of Multivariate Analysis, 2012, 104, 115-125.	0.5	0
149	Semiparametric pseudoscore for regression with multidimensional but incompletely observed regressor. Statistics in Medicine, 2018, 37, 207-217.	0.8	0
150	Response to letter by Antonio MartÃn AndrÃs on "A boundary-optimized rejection region test for the two-sample binomial problem". Statistics in Medicine, 2018, 37, 2303-2306.	0.8	0
151	How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Annals of Internal Medicine, 2021, 174, 730-731.	2.0	0
152	Analysis of Clonal Contributions to T Lymphoid and Myeloid Lineages during Early Hematopoiesis Following Autologous Transplantation in the Rhesus Macaque.. Blood, 2004, 104, 2672-2672.	0.6	0
153	The Spectrum of Human T Cell Receptor (TCR)-VÎ² Frequencies Are Established Prior to Thymic Selection.. Blood, 2004, 104, 3240-3240.	0.6	0
154	Analysis of the Human T Cell Receptor (TCR) Repertoire from Birth to Old Age Suggests That TCRVÎ² frequencies Are Established Independent of HLA.. Blood, 2005, 106, 3313-3313.	0.6	0
155	A mixture distribution approach for assessing genetic impact from twin study. Statistics in Medicine, 2022, , .	0.8	0
156	A Note on Familywise Error Rate for a Primary and Secondary Endpoint. Biometrics, 2023, 79, 1114-1118.	0.8	0